Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized and Double-blinded Trial of De-escalated Radiation in FMISO PET-selected Good Risk Versus Standard of Care Radiation in Unselected HPV Positive Oropharyngeal Cancer

NCT06563479 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT06563479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06563479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized and Double-blinded Trial of De-escalated Radiation in FMISO PET-selected Good Risk Versus Standard of Care Radiation in Unselected HPV Positive Oropharyngeal Cancer
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 3
Overall status
Recruiting
Start date
August 19, 2024
Completion date
August 31, 2027
Enrollment
291 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hpv-related squamous cell carcinoma